By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The grants are expected to be received over the next three years, commencing March 2022
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
In the interim, Deepak Khanna will lead Human Health International.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Subscribe To Our Newsletter & Stay Updated
